69 related articles for article (PubMed ID: 25182125)
41. Improving performance through knowledge translation in the Veterans Health Administration.
Francis J; Perlin JB
J Contin Educ Health Prof; 2006; 26(1):63-71. PubMed ID: 16557507
[TBL] [Abstract][Full Text] [Related]
42. Lost in knowledge translation: time for a map?
Graham ID; Logan J; Harrison MB; Straus SE; Tetroe J; Caswell W; Robinson N
J Contin Educ Health Prof; 2006; 26(1):13-24. PubMed ID: 16557505
[TBL] [Abstract][Full Text] [Related]
43. GoPubMed: exploring PubMed with the Gene Ontology.
Doms A; Schroeder M
Nucleic Acids Res; 2005 Jul; 33(Web Server issue):W783-6. PubMed ID: 15980585
[TBL] [Abstract][Full Text] [Related]
44. Recent advances with liposomes as pharmaceutical carriers.
Torchilin VP
Nat Rev Drug Discov; 2005 Feb; 4(2):145-60. PubMed ID: 15688077
[TBL] [Abstract][Full Text] [Related]
45. Fast algorithm for detecting community structure in networks.
Newman ME
Phys Rev E Stat Nonlin Soft Matter Phys; 2004 Jun; 69(6 Pt 2):066133. PubMed ID: 15244693
[TBL] [Abstract][Full Text] [Related]
46. Shattuck lecture--clinical research to clinical practice--lost in translation?
Lenfant C
N Engl J Med; 2003 Aug; 349(9):868-74. PubMed ID: 12944573
[No Abstract] [Full Text] [Related]
47. Why the impact factor of journals should not be used for evaluating research.
Seglen PO
BMJ; 1997 Feb; 314(7079):498-502. PubMed ID: 9056804
[No Abstract] [Full Text] [Related]
48. Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches.
Lowe HJ; Barnett GO
JAMA; 1994 Apr; 271(14):1103-8. PubMed ID: 8151853
[TBL] [Abstract][Full Text] [Related]
49. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin.
Fajardo-Ortiz D; Duran L; Moreno L; Ochoa H; Castaño VM
J Transl Med; 2014 Sep; 12():227. PubMed ID: 25182125
[TBL] [Abstract][Full Text] [Related]
50. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
52. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
53. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Soloman R; Gabizon AA
Clin Lymphoma Myeloma; 2008 Feb; 8(1):21-32. PubMed ID: 18501085
[TBL] [Abstract][Full Text] [Related]
54. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
Zhao M; Ding XF; Shen JY; Zhang XP; Ding XW; Xu B
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):15-26. PubMed ID: 28070993
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
56. An overview of doxorubicin formulations in cancer therapy.
Rivankar S
J Cancer Res Ther; 2014; 10(4):853-8. PubMed ID: 25579518
[TBL] [Abstract][Full Text] [Related]
57. Randomized single-agents trials in recurrent epithelial ovarian cancer.
Sessa C; Marsoni S
Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
[TBL] [Abstract][Full Text] [Related]
58. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
59. Advances in the use of nanocarriers for cancer diagnosis and treatment.
Vieira DB; Gamarra LF
Einstein (Sao Paulo); 2016; 14(1):99-103. PubMed ID: 27074238
[TBL] [Abstract][Full Text] [Related]
60. Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Plosker GL
Drugs; 2008; 68(17):2535-51. PubMed ID: 19016577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
